Immune Design is a privately held clinical stage biotechnology company based in Seattle, WA. Immune Design brings together some of the world’s leaders in the field of molecular immunology to develop a synergistic platform of next generation vaccines designed to treat cancer, infectious diseases, allergy and autoimmune disorders. The company employs leading edge technologies which target dendritic cells for more precise activation of the immune response. A novel lentiviral vector engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo and a TLR4 agonist that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces cytokines of the Th1 type to enhance the immune response.
In June 2013, the Cancer Research Institute announced its partnership with Ludwig Cancer Research and Immune Design, which will specifically focus on clinical trials to test novel combinations of immunotherapies with two investigational drugs from Immune Design's pipeline, including a synthetic Toll-like receptor 4 (TLR4) agonist adjuvant, called GLA (glucopyranosyl lipid A), and LV305, a novel lentivector-based vaccine product candidate.
To learn more, read the press release here.